C21 · Pharmaceuticals · CN
New drug approvals in China
China: 11 (first-in-class drug approvals, 2025), −77.1% on 2024.
- 11 Latest · 2025
- −77.1% vs 2024
- 70Records · 40 measures
Annual · 5 publishers · Next period 2026
First-in-class drug approvals in China
First-in-class drug approvals
China, 2022 to 2025
Every record
70 records across 40 measures, newest first within each. Each period opens its record and evidence.
Frequently asked questions
What is the latest new drug approvals figure for China?
China: 11 first-in-class drug approvals in 2025, −77.1% on 2024.
Where does the China data come from?
70 records from 12 documents by DIA, NHSA, State Council, NMPA, MOFCOM. Each figure links to its record and its original source evidence.
Cite this page
Free to reuse under CC BY 4.0 with attribution to StatOrigin and the original publisher.
StatOrigin. (2026). New drug approvals in China [Data set]. Retrieved October 28, 2026, from https://statorigin.org/statistics/new-drug-approvals/china
"New drug approvals in China." StatOrigin, 2026, https://statorigin.org/statistics/new-drug-approvals/china. Accessed 28 Oct. 2026.
StatOrigin. "New drug approvals in China." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/statistics/new-drug-approvals/china.
@misc{statorigin_new_drug_approvals_china_2026, title = {New drug approvals in China}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/statistics/new-drug-approvals/china}, note = {Data set. Accessed 2026-10-28} }